Comparative Pharmacology
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus MYTELASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus MYTELASE.
DONEPEZIL HYDROCHLORIDE vs MYTELASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
Mytelase (ambenonium chloride) is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at cholinergic synapses by inhibiting its hydrolysis. This enhances neuromuscular transmission and improves muscle strength.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
Oral: 5–25 mg three times daily; maximum 100 mg/day. IV: 2–5 mg every 2–4 hours as needed for myasthenic crisis.
None Documented
None Documented
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
3-4 hours (short; requires frequent dosing every 3-4 hours for myasthenia gravis management).
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal excretion (<5%).
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor